People: Ablynx NV (ABLX.BR)
Dr. Geert Cauwenbergh, Ph.D., is Independent Director of Ablynx NV. He is Member of the Company's Remuneration Committee and Nomination Committee. Dr. Cauwenbergh currently is Chief Executive Officer (CEO) and Chairman of RHEI Pharmaceuticals. In February 2008, Dr. Cauwenbergh founded Phases123. Prior to founding Phases123, Dr. Cauwenbergh founded Barrier Therapeutics in September of 2001. As its Chairman and CEO he raised private financing for the company in 2002 and took it public with a listing on the NASDAQ in 2004. Barrier Therapeutics was acquired by Stiefel Laboratories in 2008. Prior to founding Barrier Therapeutics, Dr. Cauwenbergh was Vice President of Technology of the Johnson & Johnson (J&J) Consumer and Personal Care Products Companies. In 1994 he became Vice President of Product Development and Member of the Board of the U.S. Johnson & Johnson Consumer Company. Dr. Cauwenbergh joined the R&D organization of the Janssen Research Foundation in Belgium in 1982, after three years in sales and marketing in Janssen Pharmaceutica. He was worldwide Director for those two franchises until 1994. Dr. Cauwenbergh is Member of the Board of Trustees, and is current Chairman of the Board of BioNJ, the industry organization for biotechnology in New Jersey, United States. In 2004, Dr. Cauwenbergh was appointed Trade Advisor for Health Care in North America to the Belgian Government, and was reconfirmed in this function in 2007. He received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, where he also completed his Masters and undergraduate work. In 2004 Dr. Cauwenbergh was inducted in the New Jersey High Tech Hall of Fame. Dr. Cauwenbergh is currently Chairman and CEO of Rhei Pharmaceuticals, Executive Chairman of ECI Biotech Inc., Managing Partner of Phases123 LLC. He also serves on the Board of Euroscreen. In the past five years, he has also served as Member of the Board of DARA Biosciences and as Chairman and CEO of Barrier Therapeutics.
|Total Annual Compensation, EUR||Long-Term Incentive Plans, EUR||All Other, EUR||Fiscal Year Total, EUR|